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AbstrAct
Background Agreement on the utility of imaging follow-
up in patients with high-risk melanoma is lacking. A UK 
consensus statement recommends a surveillance schedule 
of CT or positron-emission tomography-CT and MRI brain 
(every 6 months for 3 years, then annually in years 4 and 
5) as well as clinical examination for high-risk resected 
Stages II and III cutaneous melanoma. Our aim was to assess 
patterns of relapse and whether imaging surveillance could 
be of clinical benefit.
Patients and methods A retrospective study of patients 
enrolled between July 2013 and June 2015 from three UK 
tertiary cancer centres followed-up according to this protocol 
was undertaken. We evaluated time-to-recurrence (TTR), 
recurrence-free survival (RFS), method of detection and 
characteristics of recurrence, treatment received and overall 
survival (OS).
Results A total of 173 patients were included. Most 
(79%) had treated Stages IIIB and IIIC disease. With a 
median follow-up of 23.3 months, 82 patients (47%) had 
relapsed. Median TTR was 10.1 months and median RFS 
was 21.2 months. The majority of recurrences (66%) were 
asymptomatic and detected by scheduled surveillance scan. 
Fifty-six (68%) patients recurred with Stage IV disease, with 
a median OS of 25.3 months; 26 (31.7%) patients had a 
locoregional recurrence, median OS not reached (P=0.016). 
Patients who underwent surgery at recurrence for either 
Stage III (27%) or IV (18%) disease did not reach their median 
OS. The median OS for the 33 patients (40%) who received 
systemic therapy was 12.9 months.
Conclusion Imaging appears to reliably detect subclinical 
disease and identify patients suitable for surgery, 
conferring favourable outcomes. The short median TTR 
provides rationale to intensify imaging schedule in the first 
year of surveillance. The poor OS of patients treated with 
systemic therapy probably reflects the relatively inferior 
treatment options during this time and requires further 
evaluation in the current era.
IntRoduCtIon
The role of imaging in the follow-up of patients 
with high-risk melanoma remains unclear. It is 
still questionable whether earlier detection of 
metastatic disease translates into improvement 
in overall survival (OS) outcomes. As such, 
there is no consensus between international 
guidelines on the frequency or duration of 
imaging in this setting.1 2 This issue is increas-
ingly relevant given the advent of targeted and 
immunotherapeutic agents that improve OS in 
the management of metastatic melanoma, espe-
cially as the prognosis is superior in patients 
treated with low-volume disease.3 4 Surgical 
metastasectomy or stereotactic radiosurgery 
is also a standard of care in selected patients 
with oligometastatic disease and can achieve 
prolonged survival.5–7 Imaging is required to 
detect low-volume or asymptomatic disease in 
these cases.
Contemporary series report that patients with 
Stages II and III melanoma have a 30%–46% risk 
of disease recurrence,8–10 including asymptom-
atic distant metastases detected on imaging. Five-
year recurrence-free survival (RFS) for Stages 
IIIB and IIIC melanoma is reported at 32% and 
11%, respectively.11 A UK consensus statement 
among melanoma oncologists, published in 
2013, recommends a schedule of cross-sectional 
Key messages
What is already known about this subject?
 ► There is no global consensus on the utility of 
imaging surveillance in high-risk melanoma.
What does this study add?
 ► The current UK imaging surveillance is well-
accepted by patients, with high rate of compliance.
 ► We observed that high-risk, resected cutaneous 
melanoma has a tendency to relapse within the first 
2 years of follow-up.
 ► CT imaging reliably detects subclinical disease, 
enabling some patients to have successful 
metastasectomy.
How might this impact on clinical practice?
 ► Metastasectomy confers favourable outcome and 
should be considered in appropriately selected 
cases.
 ► A more intensive CT surveillance schedule of every 
3 months for the first year of follow-up may be 
considered.
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imaging and clinical review for patients with resected Stages 
II and III high-risk cutaneous melanoma.12 Here, we report 
the outcomes of the first group of patients followed-up 
according to this schedule across three institutions.
MetHods
study design
We performed a multicentre retrospective analysis of 
patients from three cancer centres in the UK. Clinical and 
radiological data from consecutive patients, from July 2013 
to June 2015, followed-up prospectively within the high-risk 
protocol as outlined in the Melanoma Focus Consensus 
Paper12 were noted. The recommended surveillance 
schedule consisted of CT thorax, abdomen and pelvis or 
positron emission tomography (PET)-CT scans, as well as 
MRI of the brain, at baseline postoperatively, and then at 
6-monthly intervals for 3 years, followed by annual scans to 
5 years. The study censor date was 30 June 2016.
Patient cohort
The high-risk cohort was broadly defined as patients 
with a predicted OS of less than 50% at 5 years, encom-
passing those with Stages IIC, IIIB and IIIC disease as per 
the seventh edition of the American Joint Committee 
on Cancer TNM staging system.12 13 Some patients with 
thick Stage IIB melanoma (>4 mm Breslow thickness) 
and Stage IIIA were also included at clinician discretion. 
Patients were identified by review of clinic lists and multi-
disciplinary tumour board meeting records. Characteris-
tics of their primary melanoma, molecular profiling, stage 
at the time of diagnosis of high-risk disease, the number 
of scans performed until disease recurrence, time-to-re-
currence (TTR), stage and location of recurrence, as well 
as the treatment(s) received for the recurrence episode 
were identified by medical record review.
We excluded patients with unresectable Stage III disease, 
mucosal or ocular melanoma and any patients who received 
adjuvant systemic treatment, including those recruited into 
clinical trials. Adjuvant radiotherapy was permitted.
outcomes
The key outcomes evaluated were TTR, method of detec-
tion and characteristics of recurrence, treatment received 
and OS. If patients were symptomatic at the clinical review 
where scan results were discussed, they were deemed 
symptomatic of relapse. RFS for the whole cohort was also 
determined. We sought to explore characteristics of those 
patients experiencing recurrence within the first year of 
follow-up and to characterise the group who developed 
brain metastases. Adherence to the imaging schedule was 
also evaluated.
statistical analysis
All statistical analyses were performed using SPSS V.23.0. 
Descriptive data were presented as median (interquartile 
range, IQR), mean±standard deviation (SD) and propor-
tions were expressed as a percentage. χ2 analysis was used 
to compare categorical variables, and Student’s t-test 
was used to analyse continuous variables. P values were 
two tailed. Kaplan-Meier survival analyses estimated TTR 
(defined as the time from diagnosis of high-risk disease to 
confirmed recurrence on imaging or biopsy in those who 
relapsed), RFS (same definition as TTR but encompassing 
whole cohort, including those who remained disease free 
at censor date) and OS (defined as time from diagnosis of 
high-risk disease to death from any cause).
Compliance to the surveillance schedule was calcu-
lated as a proportion of the number of scans attended 
over the theoretical number of scans expected within the 
follow-up interval. For example, after 2 years of follow-up, 
a patient would have had had four surveillance CT scans 
to achieve 100% compliance (baseline postsurgical scan 
excluded from count).
Results
Patient cohort
From July 2013 to June 2015, a total of 173 patients were 
managed according to the high-risk follow-up protocol. 
The median duration of follow-up was 23.3±8.4 months. 
The mean age was 62.5±14.9 years with 103 (59.5%) male 
patients. Table 1 outlines the baseline characteristics of 
this group. CT scan was used as the primary cross-sec-
tional imaging modality in the majority (89.0%) and 
PET-CT in the remaining patients. At least one MRI-brain 
was performed in 43.9% (n=76/173).
ttR and RFs
Overall, 82 patients (47.4%) in this cohort relapsed 
with a median TTR of 10.1 months (95% CI 8.1 to 12.1) 
(figure 1A). The median TTR for Stages IIC, IIIB and IIIC 
were 5.9 months (95% CI 1.4 to 10.4), 11.7 months (95% CI 
9.9 to 13.5) and 8.8 months (95% CI 5.6 to 12.0), respectively 
(figure 1C). There was no pairwise statistical significant 
differences between these groups (figure 1C,D). The sample 
size for Stages IIB and IIIA were inadequate for meaningful 
comparison here. The median RFS for the whole cohort was 
21.2 months (figure 1B).
Patterns of recurrence and mode of detection
Of those who relapsed (n=82), 56 (68.2%) were distant 
and 26 (31.7%) were locoregional. Relapse was Stage 
M1c in 26 patients and lactate dehydrogenase (LDH) was 
elevated in 16.7% of the 66 patients in which it was meas-
ured (n=11/66). The most common sites of metastases 
were in lymph nodes (n=49/82, 59.8%) and the lung 
(n=30/82, 36.6%) (table 2).
Recurrence was detected on imaging in 65.9% 
(n=54/82) of patients, all of whom were asymptomatic. 
Physician-detected recurrence was 22.0% (n=18/82) and 
patient-detected recurrence was 12.2% (n=10/82). The 
median number of CT (or PET-CT) scans to the detection 
of relapse was 2.
treatment on relapse
Following relapse, 87.8% (n=72/82) of patients went 
on to receive further therapy, with 51.3% (n=37/72) 
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undergoing surgery, of which 40.5% (n=15/37) were 
metastasectomies for Stage IV disease (online Supple-
mentary table S1). Of those 33 patients receiving systemic 
treatment, 48.5% (n=16/33) had BRAF mutant disease, 
62.5% (n=10/16) of whom received BRAF inhibitor 
monotherapy with dabrafenib or vemurafenib first line. 
Among the rest, 51.5% (n=17/33) received upfront 
anti-CTLA-4 (ipilimumab), 15.2% (n=5/33) received 
anti-PD-1 (pembrolizumab) and one patient received 
chemotherapy. The majority of those treated with systemic 
therapies (n=24/29 recorded, 82.8%) had normal LDH 
at time of relapse.
subgroup analyses
An exploratory subset analysis was undertaken looking at 
those who relapsed within 1 year (n=53/82, 64.6%) and 
those who relapsed after 1 year of surveillance (n=29/82, 
Table 1 Baseline characteristics of the patient cohort 
(n=173)
Characteristics
Gender
  Male 103 (59.5%)
  Female 70 (40.5%)
Age (mean) 62.5 years±14.9
Site of primary melanoma
  Head/neck 12 (6.9%)
  Torso 57 (32.9%)
  Upper limbs 30 (17.3%)
  Lower limbs 57 (32.9%)
  Unknown 17 (9.8%)
Type of primary melanoma
  Superficial spreading 91 (68.4%)
  Nodular 28 (21.1%)
  Acral 10 (7.5%)
  Lentigo maligna 2 (1.5%)
  Others 2 (1.5%)
  Unknown/missing data 40
Breslow thickness (median), n=146 3.5 mm (IQR 2.0–5.6)
Ulceration
  Present 92 (65.7%)
  Absent 48 (34.3%)
  Unknown/missing data 33
Mitoses
  Yes 92 (89.3%)
  No 11 (10.7%)
  Unknown/missing data 70
American Joint Committee on Cancer stage at diagnosis of 
high risk
  IIB 3 (1.7%)
  IIC 32 (18.5%)
  IIIA 1 (0.6%)
  IIIB 88 (50.9%)
  IIIC 49 (28.3%)
BRAF mutation status
  Mutant 54 (34.8%)
  Wild type 101 (65.2%)
  Unknown/missing data 18
Table 2 Patterns of recurrence (n=82)
Description of recurrence
Disease recurrence
  Yes 82 (47.4%)
  No 91 (52.6%)
Time-to-recurrence (median) 10.1 months (95% CI 
8.1 to 12.1)
Number of scans to recurrence 
(median)
2 (1;3)
Detection of recurrence
  Patient detected/symptomatic 10 (12.2%)
  Physician detected on examination 18 (22.0%)
  Imaging/asymptomatic 54 (65.9%)
American Joint Committee on Cancer stage at diagnosis of 
high risk
  IIB 2 (2.4%)
  IIC 11 (13.4%)
  IIIA 1 (1.2%)
  IIIB 34 (41.5%)
  IIIC 34 (41.5%)
BRAF mutation status, n=88
  Mutant 30 (34.1%)
  Wild type 58 (65.9%)
Substage breakdown of recurrence
  Locoregional 26 (31.7%)
  M1a 13 (15.9%)
  M1b 17 (20.7%)
  M1c 26 (31.7%)
Site of recurrence
  Subcutaneous 22 (26.8%)
  Lymph nodes 49 (59.8%)
  Lung 30 (36.6%)
  Liver 18 (22.0%)
  Bone 6 (7.3%)
  Brain 6 (10.9%)*
  Others 9 (11.0%)
Lactate dehydrogenase at recurrence, n=66
  >Upper limit of normal (ULN) 11 (16.7%)
  Normal or <ULN 55 (83.3%)
*Brain-only recurrence in N=2 (33.3%). 
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35.4%). There was no significant difference observed 
in demographic profile, method of recurrence detec-
tion, stage at recurrence and type of treatment received 
(online Supplementary table S2 and S3).
Six patients (n=6/82, 7.3%) relapsed in the brain at 
time of diagnosis of their recurrence (online Supple-
mentary table S4). Two patients relapsed with brain-only 
disease and were symptomatic at time of presentation. 
Both had a normal LDH.
overall survival
The median OS for the whole cohort was not reached 
(figure 2A). Among those who had recurrent disease 
(n=82), median OS was not reached and 63.1% are 
alive at 2 years (figure 2B). Substage analysis showed 
that median OS was not reached for those relapsing 
with Stage III disease and was 25.3 months (95% CI 21.2 
to 29.5, P=0.016) for those with a Stage IV disease at 
relapse (figure 2C). The median OS among those who 
received systemic therapies was 12.9 months (95% CI 2.6 
to 23.2). For patients having surgery for relapsed disease, 
the median OS was not reached and 80.3% were alive at 
2 years (figure 2D). There was no statistically significant 
difference (P=0.971) in median OS between those who 
had surgery for Stage III (n=22/37, 59.5%) versus Stage 
IV (n=15/37, 40.5%) relapse (figure 2E).
Adherence to the surveillance schedule
For surveillance CT and PET-CT scans, the majority of 
patients (n=156/173, 90.2%) attended all their scans on 
time as per protocol intervals (100% compliance), and 
no patients were lost to follow-up. The median number of 
scans missed for the remaining 9.8% (n=17/173) was one 
scan. The median number of CT (or PET-CT) scans to 
detection of recurrence was two (range 1–5 scans).
There was a much lower adherence to MRI brain 
surveillance where 97 patients (56.1%) did not have 
any brain imaging during their follow-up. Among the 
76 patients (43.9%) in whom at least one brain scan was 
performed, 57.9% (n=44/76) were 100% compliant. The 
median number of scans missed for the remaining 42.1% 
(n=32/76) was one scan.
dIsCussIon
Our findings demonstrate that patients with high-risk 
cutaneous melanoma (79% Stages IIIB and IIIC) have 
a high rate of recurrence (47%), consistent with other 
reported series.8 10 In our cohort, the majority of patients 
(65%) relapsed within 1 year of curative surgery for ‘high-
risk’ disease. Our exploratory subanalysis did not find any 
significant predictors of relapse before 12 months. The 
median TTR of 10.1 months is shorter than the 17 months 
reported by Podlipnik et al in their series of 290 patients 
but they had a greater proportion of Stage II cases (37% vs 
20%).10 Although fewer in number (n=11), patients with 
Stage IIC disease who relapsed had a particularly short 
median TTR of 5.9 months, shorter than the median of 
8.8 months for Stage IIIC (n=34; figure 1C). This supports 
application of the same imaging surveillance schedule in 
this group.
The RFS of our overall cohort (21.2 months) was 
longer than the RFS in the placebo arms of the adjuvant 
dabrafenib and trametinib trial (16.6 months) and RFS 
in the adjuvant ipilimumab trial (17.1 months), despite 
our population containing a greater proportion of 
Stages IIIB and IIIC patients.14 15 Most likely this is due 
to three monthly scans performed in these large regis-
tration studies versus six monthly scans in our cohort. 
The median OS of the patients in these placebo arms was 
not reached; however, OS by first treatment received at 
relapse is not available. Interestingly, in these two adju-
vant trials, 22%–50% of patients in the placebo arms who 
relapsed were not recorded as receiving further anti-
cancer therapy, whereas in our study only 15% received 
best supportive care. Whether more regular surveillance 
imaging improves survival through earlier detection 
remains to be elucidated; therefore, outside of trials, 
three monthly scans with the additional radiation expo-
sure increased financial costs and scan anxiety will need 
to be carefully considered.
Most relapses in our cohort (68%) were detected on 
surveillance scans, with 88% being asymptomatic of their 
disease. The main sites of relapse were lymph nodes, 
lung and skin and subcutaneous tissues, consistent with 
others.10 Most patients who relapsed (68%) had meta-
static disease, with the smaller proportion (32%) having 
locoregional disease. Although the detection of relapse 
depended on imaging for the majority of our group, 
clinical review and patient education regarding signs 
of potential relapse remain important. In the series by 
Romano et al,11 only 32% of relapses were detected by 
imaging overall, but most systemic relapses were detected 
in this manner. In their series in which the frequency of 
scans was not defined, patients detected 47% and doctors 
21% of relapses.11
The outcomes for patients who underwent surgery at 
relapse were very good. Surgery was the most commonly 
used treatment in those with locoregional disease (85%). 
The median OS of those who relapsed with Stage III 
disease was not reached, with 78% alive at 2 years. This 
is higher than previously reported13 and may reflect 
changes in surgical management over time, such as 
more frequent ilioinguinal lymph node dissections. Of 
particular note, 27% of patients with a Stage IV relapse 
also underwent surgery as their initial treatment. The 
median OS of 25.3 months for all patients who relapsed 
with Stage IV disease was mostly attributable to the excel-
lent survival of this surgically managed group whose 
median (not reached) and landmark (80% at 2 years) 
OS figures were no different to the surgically managed 
Stage III patients. This is superior to the median OS of 
21 months (with 5 years of follow-up) reported in a series 
of 64 patients who were rendered disease free by metas-
tasectomy.5 A third of our surgically treated patients 
remained disease free at the time of censoring, including 
53% (n=8/15) who underwent metastectomy. Superior 
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outcomes with surgically resectable recurrence have been 
reported in other imaging surveillance series11 16 and 
most likely this is due to better prognostic factors such 
as lower volume, slower tempo disease. Our results rein-
force the ongoing role of surgical management including 
metastasectomy and suggest these patients are being 
appropriately selected.
Patients who were treated with systemic therapy had 
a relatively poor outcome in our cohort, with a median 
OS of 12.9 months. This is likely most likely explained 
by the predominance of monotherapy (52% ipilim-
umab, 15% anti-PD-1, 30% BRAF inhibitor), reflecting 
access to treatment outside of clinical trials in the UK 
at that time. None of the patients received combination 
targeted or immunotherapy. Ipilimumab only became 
available in the first line setting in July 2014 and a subse-
quent audit reported a median OS of 6 months for these 
patients managed outside of clinical trials.17 Vemurafenib 
became available in December 2012 and the vemurafenib 
access programmes reported a median OS of 10.5–
12.1 months.18 19 Anti-PD-1 therapy only became available 
in the second line in late 2016 and in untreated patients 
in mid-2017. However, given both the lead time afforded 
by imaging and the fact that the majority of patients were 
asymptomatic and had a normal LDH, these results are 
disappointing.
Although there was no formal prospective assessment 
of the acceptability of regular imaging, the high rate of 
compliance with CT/PET-CT imaging suggests that this is 
a feasible schedule for patients to undertake. The reason 
for such poor adherence to MRI imaging cannot be accu-
rately determined from this retrospective data and we 
cannot comment on the value of screening for central 
nervous system metastases. The rate of brain metastases 
in the relapsed cohort (n=6/82, 7%) is within the range 
of 4%–13% reported in other series.11 Analysis of subse-
quent patient cohorts surveilled by our schedule will be 
more informative if adherence has improved over time.
In contrast with others,9–11 our contemporary cohort 
had targeted and immunotherapy treatments available on 
relapse, although treatment options have improved signifi-
cantly since then. Unlike the Romano et al11 and Lewin et 
al9 series, we also included patients with Stage IIC whose 
prognosis is worse than those with Stage IIIA disease.13 
Meaningful subgroup analyses are limited, however, due 
to small numbers of Stage II patients. The approach with 
imaging was consistent and adherence to the schedule 
was analysed, unlike in the other cohorts. This is an anal-
ysis of a prospective policy that relied on retrospective 
medical record review and therefore is subject to quality 
of the data entry and collection. We acknowledge that 
our median follow-up period of 23 months is relatively 
short. Also, the landscape of management of resected 
Stage III patients has recently changed with the advent 
of systemic adjuvant treatments superior than interferon 
in efficacy and tolerability. Ipilimumab has been shown 
to improve overall survival compared with placebo20; 
however, nivolumab has recently demonstrated improved 
recurrence-free survival compared with ipilimumab.21 The 
combination of dabrafenib and trametinib also improves 
recurrence-free survival over placebo.15 Although there 
will remain a role for imaging surveillance after a course 
of adjuvant therapy, these treatments are likely to impact 
the natural history of subsequent relapse.
ConClusIons
Patients with high-risk Stage II and III melanoma have a 
substantial relapse rate within the first 2 years of follow-up, 
with the majority of relapses detected by imaging surveil-
lance. Imaging assists in the detection of subclinical 
disease, facilitating successful metastasectomy in some 
cases. Considering the short TTR in our study, we recom-
mend a more intensive CT surveillance schedule of every 
3 months for the first year. Effective adjuvant therapy will 
likely alter the natural history of relapse, but currently 
no adjuvant agents are funded in the UK. Biomarkers 
including circulating tumour DNA may also further 
refine clinical management in this high-risk population.
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